Dr Jason Webber and his team at Swansea University are tackling early intervention for aggressive prostate cancer, developing a simple and highly promising blood test to identify men with high-risk prostate cancer earlier and more accurately.

Prostate cancer is the most commonly diagnosed cancer among men in the UK, with over 50,000 new cases every year. While many prostate cancers grow slowly and may never cause harm, a significant proportion are far more aggressive – and early intervention is vital.

Current diagnostic tools, including Prostate-Specific Antigen (PSA) testing and imaging, are incredibly useful but far from perfect. They can miss more aggressive forms of the disease or lead to overtreatment of cancers that may never become life-threatening. For patients and clinicians, distinguishing between low-risk and aggressive cancers is a critical yet unresolved issue in prostate cancer care.

Backed by funding from the Medical Research Council’s Impact Acceleration Account, Dr Webber’s research is focused on creating a new diagnostic test that uses a small sample of blood to detect tiny biomarkers known as extracellular vesicles (EVs). These microscopic particles are released by prostate cancer cells and enter the bloodstream, carrying molecular information about the tumour’s behaviour.

By isolating and analysing these vesicles, Dr Webber’s team can identify molecular signatures that are linked specifically to aggressive disease. The result: a minimally invasive test that could either strengthen the conclusions of existing diagnostics or, in many cases, identify dangerous cancers much earlier than current methods.

One of the key strengths of this approach lies in its ability to add confidence to diagnosis. For patients with ambiguous test results or those under active surveillance, the EV-based blood test could tip the balance – helping clinicians decide who needs urgent treatment and who can safely avoid unnecessary interventions.

The test is still under development, but early results are promising. The team has successfully identified EV-based markers linked to aggressive prostate cancer in clinical samples. The next steps include refining the test for broader clinical use, validating it across larger patient groups, and working toward potential clinical trials.

If successful, this work could significantly reduce the burden of prostate cancer by:

• Accelerating the identification of high-risk patients;
• Reducing unnecessary treatments and their associated side effects;
• Improving patient outcomes through timely intervention.

This project embodies the mission of the National Network for Innovation in Sport and Health: supporting forward-thinking research that translates into real-world health impact. By focusing on non-invasive, precision diagnostics, this research is set to redefine how we approach prostate cancer care in the UK and beyond.